The new normal: Immunomodulatory agents against sepsis immune suppression

Trends in Molecular Medicine

Volumn 20, Issue 4, 2014, Pages 224-233

  Hutchins, Noelle A ^a   Unsinger, Jacqueline ^b   Hotchkiss, Richard S ^b   Ayala, Alfred ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Co inhibitory molecules; Cytokines; Immunomodulatory agents; Immunosuppression; Sepsis

Indexed keywords

BIM PROTEIN; CASPASE 8; CELL SURFACE MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTOXIN ANTIBODY; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 7; PROTEIN BCL 2; PROTEIN BID; PUMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACINETOBACTER; APOPTOSIS; CANDIDA; CELL SURFACE; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; CYTOKINE STORM; CYTOMEGALOVIRUS; CYTOTOXICITY; DENDRITIC CELL; ENTEROCOCCUS; HEALTH CARE COST; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NONHUMAN; PSEUDOMONAS; REVIEW; SEPSIS; STENOTROPHOMONAS; T LYMPHOCYTE; TISSUE REACTION; UPREGULATION; VIRULENCE;

ANIMALIA; BACTERIA (MICROORGANISMS);

CO-INHIBITORY MOLECULES; CYTOKINES; IMMUNOMODULATORY AGENTS; IMMUNOSUPPRESSION; SEPSIS;

ANIMALS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; SEPSIS;

EID: 84897378109     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.01.002     Document Type: Review

References (94)

1. Angus D.C., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
2. Martin G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003, 348:1546-1554.
3. Gaieski D.F., et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013, 41:1167-1174.
4. Vincent J.L., et al. Sepsis definitions: time for change. Lancet 2013, 381:774-775.
5. Ward N.S., et al. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin. Chest Med. 2008, 29:617-625. viii.
6. Abraham E., et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997, 277:1531-1538.
7. Opal S.M., et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013, 309:1154-1162.
8. Osuchowski M.F., et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 2006, 177:1967-1974.
9. Hotchkiss R.S., et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013, 13:862-874.
10. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003, 348:138-150.
11. Otto G.P., et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 2011, 15:R183.
12. Volk H.D., et al. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem. Immunol. 2000, 74:162-177.
13. Reber A.J., et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis. 2012, 3:68-90.
14. Kollef K.E., et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008, 134:281-287.
15. Luyt C.E., Kaiser L. Virus detection in patients with severe pneumonia: still more questions than answers?. Am. J. Respir. Crit. Care Med. 2012, 186:301-302.
16. Limaye A.P., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
17. Hotchkiss R.S., et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14541-14546.
18. Hotchkiss R.S., et al. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit. Care Med. 1997, 25:1298-1307.
19. Hotchkiss R.S., et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 2005, 174:5110-5118.
20. + T lymphocytes in humans. J. Immunol. 2001, 166:6952-6963.
21. Coopersmith C.M., et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002, 287:1716-1721.
22. Chung C.S., et al. Deficiency of Bid protein reduces sepsis-induced apoptosis and inflammation, while improving septic survival. Shock 2010, 34:150-161.
23. Wesche-Soldato D.E., et al. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005, 106:2295-2301.
24. Chung C.S., et al. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J. Leukoc. Biol. 2003, 74:344-351.
25. Hotchkiss R.S., et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 2000, 1:496-501.
26. Coopersmith C.M., et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit. Care Med. 2002, 30:195-201.
27. Venet F., et al. Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit. Care Med. 2013, 41:111-119.
28. Hutchins N.A., et al. Kupffer cells protect liver sinusoidal endothelial cells from Fas-dependent apoptosis in sepsis by down-regulating gp130. Am. J. Pathol. 2013, 182:742-754.
29. McNeal S.I., et al. The dual functions of receptor interacting protein 1 in Fas-induced hepatocyte death during sepsis. Shock 2011, 35:499-505.
30. London N.R., et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci. Transl. Med. 2010, 2:23ra19.
31. Harrison C. Sepsis: calming the cytokine storm. Nat. Rev. Drug Discov. 2010, 9:360-361.
32. Hotchkiss R.S., et al. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009, 15:496-497.
33. Boomer J.S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
34. Hotchkiss R.S., et al. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 2013, 13:260-268.
35. Hotchkiss R.S., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999, 27:1230-1251.
36. Huang X., et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6303-6308.
37. Venet F., et al. Regulatory T cell populations in sepsis and trauma. J. Leukoc. Biol. 2008, 83:523-535.
38. Landelle C., et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 2010, 36:1859-1866.
39. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 2004, 22:625-655.
40. + severe combined immunodeficiency. Nat. Genet. 1998, 20:394-397.
41. + thymic emigrants to IL-7 therapy. Blood 2013, 121:4684-4693.
42. + T cells during the acute phase of SIV infection in Rhesus macaques. PLoS Pathog. 2012, 8:e1002636.
43. + effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 2010, 130:418-426.
44. Unsinger J., et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 2010, 184:3768-3779.
45. Li W.Q., et al. Interleukin-7 regulates Bim proapoptotic activity in peripheral T-cell survival. Mol. Cell. Biol. 2010, 30:590-600.
46. Venet F., et al. IL-7 restores lymphocyte functions in septic patients. J. Immunol. 2012, 189:5073-5081.
47. Sportes C., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 2008, 205:1701-1714.
48. Morre M., Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol. 2012, 7:55-68.
49. Mackall C.L., et al. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 2011, 11:330-342.
50. + T-cell responses when immunizing with multiepitope peptide vaccines. J. Immunother. 2006, 29:224-231.
51. Sportes C., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 2010, 16:727-735.
52. Lundstrom W., et al. IL-7 in human health and disease. Semin. Immunol. 2012, 24:218-224.
53. Levy Y., et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin. Infect. Dis. 2012, 55:291-300.
54. Lu J., et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 2002, 8:3877-3884.
55. Ochoa M.C., et al. Interleukin-15 in gene therapy of cancer. Curr. Gene Ther. 2013, 13:15-30.
56. Pelletier M., et al. Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases-1/2. FEBS Lett. 2002, 532:164-170.
57. Waldmann T.A., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in Rhesus macaques. Blood 2011, 117:4787-4795.
58. Yu P., et al. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 2010, 16:6019-6028.
59. Steel J.C., et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res. 2010, 70:1072-1081.
60. Inoue S., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 2010, 184:1401-1409.
61. Kim H.C., et al. Role of IL-15 in sepsis-induced skeletal muscle atrophy and proteolysis. Tuberc. Respir. Dis. (Seoul.) 2012, 73:312-319.
62. Alves-Filho J.C., et al. Neutrophil paralysis in sepsis. Shock 2010, 34(Suppl. 1):15-21.
63. Kovach M.A., Standiford T.J. The function of neutrophils in sepsis. Curr. Opin. Infect. Dis. 2012, 25:321-327.
64. Cummings C.J., et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J. Immunol. 1999, 162:2341-2346.
65. Stephan F., et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit. Care Med. 2002, 30:315-322.
66. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009, 30:475-487.
67. Manjuck J., et al. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J. Lab. Clin. Med. 2000, 135:153-160.
68. Meisel C., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 2009, 180:640-648.
69. Hall M.W., et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011, 37:525-532.
70. Freeman G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
71. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013, 13:227-242.
72. Ceeraz S., et al. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013, 34:556-563.
73. Day C.L., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
74. Hirano F., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65:1089-1096.
75. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
76. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
77. Laudanski K., et al. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15564-15569.
78. Brahmamdam P., et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 2010, 88:233-240.
79. Zhang Y., et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care 2010, 14:R220.
80. Huang X., et al. Identification of B7-H1 as a novel mediator of the innate immune/pro-inflammatory as well as a possible myeloid prognostic marker in sepsis. J. Immunol. 2013, 10.4049/jimmunol.1302252.
81. Chang K.C., et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care 2013, 17:R85.
82. Zhang Y., et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit. Care 2011, 15:R70.
83. Guignant C., et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care 2011, 15:R99.
84. Inoue S., et al. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011, 36:38-44.
85. Shubin N.J., et al. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J. Leukoc. Biol. 2012, 92:593-603.
86. Kobayashi Y., et al. B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5121-5126.
87. + T-cells associates with sepsis and subsequent infections in ICU patients. Crit. Care 2013, 17:R276.
88. Ayala A., et al. Sepsis-induced potentiation of peritoneal macrophage migration is mitigated by programmed cell death receptor-1 gene deficiency. J. Innate Immun. 2014, 10.1159/000355888.
89. Duraiswamy J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73:3591-3603.
90. Zinselmeyer B.H., et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.
91. Hutchins N.A., et al. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. J. Leukoc. Biol. 2013, 94:963-970.
92. Zhu W., et al. PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. Mediators Inflamm. 2013, 2013:361501.
93. Watanabe N., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 2003, 4:670-679.
94. Okazaki T., et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13866-13871.